预靶向：连接两个世界的放射性药物探针

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-04-28 DOI:10.1158/1078-0432.ccr-25-0568

Yuriko Mori, Jens Cardinale, Frederik L. Giesel

{"title":"预靶向：连接两个世界的放射性药物探针","authors":"Yuriko Mori, Jens Cardinale, Frederik L. Giesel","doi":"10.1158/1078-0432.ccr-25-0568","DOIUrl":null,"url":null,"abstract":"The human trophoblast cell-surface antigen 2 (Trop-2) is expressed in a variety of malignant diseases. Using pretargeting methodology, a novel antibody against Trop-2 was radiolabeled and evaluated in a preclinical setting. This showed promising characteristics lending itself as potential basis for further clinical trials as imaging agent and potential theranostic.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"43 1","pages":""},"PeriodicalIF":10.0000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pretargeting: Bridging the two worlds of radiopharmaceutical probes\",\"authors\":\"Yuriko Mori, Jens Cardinale, Frederik L. Giesel\",\"doi\":\"10.1158/1078-0432.ccr-25-0568\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The human trophoblast cell-surface antigen 2 (Trop-2) is expressed in a variety of malignant diseases. Using pretargeting methodology, a novel antibody against Trop-2 was radiolabeled and evaluated in a preclinical setting. This showed promising characteristics lending itself as potential basis for further clinical trials as imaging agent and potential theranostic.\",\"PeriodicalId\":10279,\"journal\":{\"name\":\"Clinical Cancer Research\",\"volume\":\"43 1\",\"pages\":\"\"},\"PeriodicalIF\":10.0000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1078-0432.ccr-25-0568\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.ccr-25-0568","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

人滋养细胞表面抗原2 （Trop-2）在多种恶性疾病中表达。使用预靶向方法，一种针对Trop-2的新型抗体被放射性标记并在临床前环境中进行评估。这显示了有希望的特征，为进一步的临床试验提供了潜在的基础，作为显像剂和潜在的治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pretargeting: Bridging the two worlds of radiopharmaceutical probes

The human trophoblast cell-surface antigen 2 (Trop-2) is expressed in a variety of malignant diseases. Using pretargeting methodology, a novel antibody against Trop-2 was radiolabeled and evaluated in a preclinical setting. This showed promising characteristics lending itself as potential basis for further clinical trials as imaging agent and potential theranostic.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.